Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668]
Main Authors: | Tianyao Lei, Tianwei Xu, Niu Zhang, Xiaoteng Zou, Ziyue Kong, Chenchen Wei, Zhaoxia Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | Pharmacological Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661823002785 |
Similar Items
-
TAPO in first‐line osimertinib therapy and continuation of osimertinib
by: Chihiro Mimura, et al.
Published: (2023-02-01) -
Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis
by: Guojin Zhou, et al.
Published: (2024-01-01) -
Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01) -
Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
by: Yuan‐Ling Cheng, et al.
Published: (2022-08-01) -
PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC
by: Kavya Sri Racherla, et al.
Published: (2023-07-01)